Can Mirabegron (Myrbetriq) be taken as 50 mg in the morning and 25 mg in the evening?

Mirabegron Split Dosing is NOT Recommended

Mirabegron (Myrbetriq) should NOT be taken as 50 mg in the morning and 25 mg in the evening (total 75 mg/day). The FDA-approved dosing is either 25 mg or 50 mg once daily as a single dose, not split dosing 1.

Why This Dosing Regimen is Problematic

Lack of Evidence for Split Dosing

• All clinical trials establishing mirabegron's efficacy and safety used once-daily dosing at fixed doses (25 mg, 50 mg, or 100 mg) 2, 3
• The pharmacokinetics of mirabegron were studied with once-daily administration, reaching steady-state within 7 days of this regimen 1
• No clinical trials have evaluated split dosing or the specific 75 mg total daily dose you're proposing

Exceeds Standard Dosing

• The proposed total daily dose of 75 mg exceeds the maximum FDA-approved dose of 50 mg once daily for adult OAB 1
• Doses above 50 mg (100 mg, 200 mg) were studied but showed dose-dependent increases in blood pressure and heart rate without proportional efficacy benefits 1

Safety Concerns with Higher Doses

The FDA label clearly documents dose-dependent adverse effects 1:

• Blood pressure increases: At 50 mg, mean SBP increased 3.0 mm Hg; at 100 mg, 5.5 mm Hg; at 200 mg, 9.7 mm Hg
• Heart rate increases: At 50 mg, mean increase was 6.7 bpm; at 100 mg, 11 bpm; at 200 mg, 17 bpm
• QTc prolongation: More pronounced at doses above 50 mg, particularly in females

Correct Dosing Strategy

Standard Approach

• Start with 25 mg once daily (single morning dose)
• If inadequate response after 4-8 weeks, escalate to 50 mg once daily 4
• This dose escalation strategy (25 mg → 50 mg) is supported by evidence showing improved outcomes in patients with residual urgency or urgency urinary incontinence 4

Timing Considerations

Recent evidence suggests timing may matter 5:

• Nighttime dosing (single 25 mg dose at bedtime) showed greater benefit for nocturia and morning urgency episodes
• Daytime dosing showed better improvement in emotional quality of life measures
• However, both were single daily doses, not split dosing

Combination Therapy Alternative

If 50 mg once daily is insufficient, the evidence-based next step is 2:

• Add an antimuscarinic (e.g., solifenacin 5 mg) to mirabegron 50 mg once daily
• The SYNERGY I/II and BESIDE trials demonstrated superior efficacy with this combination without significant safety concerns
• This is a Grade B recommendation from the 2019 AUA/SUFU guidelines

Common Pitfalls to Avoid

1. Do not create custom dosing regimens without clinical trial evidence—mirabegron has non-linear pharmacokinetics, making dose predictions unreliable 1

2. Do not exceed 50 mg total daily dose in routine practice—higher doses increase cardiovascular risks without established benefit-risk ratio

3. Do not split doses—the extended-release formulation is designed for once-daily administration with specific pharmacokinetic profiles

Bottom Line

Use mirabegron 25 mg or 50 mg once daily (not split). If 50 mg once daily is inadequate, add solifenacin 5 mg rather than increasing mirabegron dose further 2. Consider nighttime dosing if nocturia is the predominant symptom 5.